Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer. 2018

Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
Epidemiology and Cardiology Research Group, Department of Health Sciences, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer. An important barrier to the use of TMX is the development of drug resistance caused by molecular processes related to genetic and epigenetic mechanisms, such as the actions of cytochrome P450 2D6 (CYP2D6) polymorphisms and of its metabolites. The present study aimed to review recent findings related to the impact of CYP2D6 polymorphisms and how they can affect the results of TMX in breast cancer treatment. The keywords CYP2D6, tamoxifen, and breast cancer were searched in the PubMed, Scopus, The Cochrane Library, Scielo, and Bireme databases. Studies related to other types of neoplasms or based on other isoenzymes from cytochrome P450, but not on CYP2D6, were excluded. The impact of CYP2D6 polymorphisms in the TMX resistance mechanism remains unclear. The CYP2D6 gene seems to contribute to decreasing the efficacy of TMX, while the main mechanism responsible for therapy failure, morbidity, and mortality is the progression of the disease.

UI MeSH Term Description Entries
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D019389 Cytochrome P-450 CYP2D6 A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population. CYP2D6,Debrisoquine 4-Hydroxylase,Debrisoquine Hydroxylase,CYP 2D6,Cytochrome P450 2D6,Debrisoquine 4-Monooxygenase,Imipramine 2-Hydroxylase,Sparteine Monooxygenase,2-Hydroxylase, Imipramine,4-Hydroxylase, Debrisoquine,4-Monooxygenase, Debrisoquine,CYP2D6, Cytochrome P-450,Cytochrome P 450 CYP2D6,Debrisoquine 4 Hydroxylase,Debrisoquine 4 Monooxygenase,Hydroxylase, Debrisoquine,Imipramine 2 Hydroxylase,Monooxygenase, Sparteine,P-450 CYP2D6, Cytochrome,P450 2D6, Cytochrome

Related Publications

Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
January 2009, Journal of toxicology and environmental health. Part B, Critical reviews,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
August 2009, The pharmacogenomics journal,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
June 2000, Clinica chimica acta; international journal of clinical chemistry,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
December 1993, Pharmacogenetics,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
November 1999, Clinical pharmacology and therapeutics,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
January 1993, British journal of clinical pharmacology,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
June 2005, Biological & pharmaceutical bulletin,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
January 2015, International journal of clinical and experimental medicine,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
July 1998, British journal of clinical pharmacology,
Lucas Soares Bezerra, and Marcelo Antônio Oliveira Santos-Veloso, and Natanael da Silva Bezerra Junior, and Lucilia Carvalho da Fonseca, and Wivianne Lisley Andrade Sales
February 2011, Current drug safety,
Copied contents to your clipboard!